The mucopolysaccharidoses are a group of inherited metabolic disorders that are renowned for presenting clinical problems, particularly related to cardiac, airway, and skeletal abnormalities, in children during anaesthesia. The changing clinical management of the mucopolysaccharidoses can be described in three phases. An initial phase of accumulation and dissemination of knowledge about the management of this rare disease with a growing recognition that untreated Hurler syndrome and more severe forms of other phenotypes such as Hunter syndrome and Maroteaux-Lamy syndrome were associated with severe complications under anaesthesia. This was followed by a second phase reflecting the beneficial results of new treatments such as haemopoietic stem cell transplantation and enzyme replacement therapy. Early and successful transplantation has dramatically improved long-term outcome and reduced anaesthetic complications in children with Hurler syndrome. Enzyme replacement therapy is available for many forms of mucopolysaccharidosis. If commenced at an early age improvement in many organ systems may be observed with an improved quality of life. However, these current treatment regimens do not appear to improve neurocognitive dysfunction, or cardiac valvular or skeletal abnormalities. We are now entering a third phase where the partial benefits of these treatment regimens are resulting in an increasing number of older patients with partially corrected abnormalities, including difficult airways, presenting for ongoing treatment to a new and potentially unsuspecting group of clinicians. Major airway abnormalities may be encountered and current adult guidelines may need to be adapted. A multidisciplinary team approach involving paediatric and adult anaesthetists is recommended to optimise future management.
Introduction
The mucopolysaccharidoses (MPS) are a group of rare inherited disorders of metabolism that produce a characteristic phenotype presenting with multiple problems, particularly airway related, at anaesthesia [1] [2] [3] [4] [5] . Glycosaminoglycans (GAGs) are a group of polymerised sugar-protein molecules that play an important part in the construction of the cellular and extracellular matrix in most organs and systems in the human body together with a role in cellular communication. Specific lysosomal enzymes play a key role in the regulation of the natural cellular production and breakdown of these GAGs. In each affected case a defective gene leads to the loss of the enzyme required to break down the relevant GAG leading to the accumulation of GAGs and GAG fragments with subsequent dysfunction on a cellular level and abnormal overgrowth, distortion and consequent obstruction at an organ level ( Table 1) .
The physical characteristics associated with each type of MPS are dependent upon the specific deficient enzyme and the relative importance of the subsequent accumulated GAG within each organ system [1] [2] [3] [4] [5] . The history of the medical and anaesthetic management of children with MPS can best be described in three sequential but overlapping phases; such phases are not meant to represent distinct time periods but rather periods of clinical practice during which clinical management, including anaesthesia, was influenced by the then current knowledge and subsequently the results of treatment options prevailing at the time. Phase one commenced with a period of gathering and subsequent sharing of knowledge regarding a rare but extremely problematic disease [6] [7] [8] [9] . This was followed by a second phase characterised by the widespread acknowledgement of potential airway, respiratory and cardiac problems associated with anaesthesia together with the application of proven therapeutic medical techniques to improve survival and quality of life. The third, ongoing phase, constitutes a growing recognition amongst specialists that some of the previously accepted anaesthetic problems associated with the management of MPS disease are becoming increasingly rare but have been replaced by new sets of issues that are likely to confront a potentially new and unsuspecting group of clinicians.
Phase one (the accumulation of knowledge)
The 1980/90s saw an increasing awareness of the problems that these children presented for anaesthesia with several centres publishing their accumulated experience of these cases [6] [7] [8] [9] . Care should be taken when studying these and subsequent reports, especially when trying to compare practice and experiences. All of these reports are retrospective and relate to relatively small numbers of patients. The possibility of a single type of MPS or an individual patient distorting data should be borne in mind. Although some report experience regarding only one type of MPS (in particular MPS IH, Hurler syndrome) and so contain a more homogeneous group, most describe a mixed group of MPS types. Despite these potential confounding factors a clear pattern of problems emerged: children with MPS often presented with significant airway, and sometimes cardiac, abnormalities. Children with Hurler syndrome (MPS IH) and those with severe forms of Hunter syndrome (MPS II) and Maroteaux-Lamy syndrome (MPS VI) presented the highest risk and this risk increased with the age of the child [6] [7] [8] [9] . The potential for severe, multi-level airway obstruction 4, 5 produced particular concern surrounding the problems of difficult intubation and the creation of a can't intubate, can't oxygenate situation. In an attempt to avoid this some clinicians have advocated the use of spontaneous ventilation, usually with a volatile agent, until a definitive airway has been established 8 . In addition, the use of the laryngeal mask (LM) either as a definitive airway or as a conduit for a fibreoptic bronchoscopic (FOB) intubation has proved safe and reliable 8, 10 . The combined LM/FOB technique in particular offers the advantages of minimising disruption to oxygenation and anaesthesia, retaining the ability to change endotracheal tubes (ETT) without loss of an airway and sometimes gives valuable information regarding laryngeal and tracheal disease that may alter management 10, 11 . Problems at extubation with partial or complete obstruction resulting in negative pressure pulmonary oedema and hypoxaemia have been well recognised 12 .
Phase two
There have been two significant breakthroughs in the medical treatment of children with MPS.
Haemopoietic stem cell transplantation (HSCT)
Although HSCT, in the form of bone marrow transplant (BMT), was first attempted for Hurler syndrome over 30 years ago, the past 15 years have seen a large increase in numbers and success rates for HSCT (either autologous BMT or umbilical stem cell transplant), both in terms of successful engraftment and reduction in transplant-related morbidity and mortality 13, 14 . Successful engraftment of donor cells leads to the recipient producing their own enzyme and a significant improvement in many organ systems and overall function. However there are significant differences between organ systems in terms of reversal of established disease and prevention of ongoing deterioration. Studies have shown significant improvements in appearance, specific physiological parameters and quality of life measurements following successful engraftment, particularly in the MPS IH patients 13, 14 . These improvements have occurred as a consequence of a reduction of GAG deposition in the respiratory (upper and lower airways) and cardiac (myocardium) systems, and reduction in hepatosplenomegaly.
Successful transplantation would not, however, appear to lead to the significant resolution of skeletal, cardiac valvular or neurocognitive dysfunction, especially when already well established. Knowledge of these factors has led to the publication of clear consensus guidelines recommending that where an appropriate donor is available, HSCT should be instituted before two years of age in an attempt to treat the condition before significant neurocognitive decline has already occurred [13] [14] [15] . Successful engraftment at an even earlier age, perhaps with HLA-matched unrelated donor cells, may result in an even better global improvement 14 . The limited improvement in some organ systems has meant that HSCT has not so far found a significant role in the treatment of some forms of MPS, notably severe MPS II (Hunter syndrome) and MPS III (Sanfilippo syndrome) that are often characterised by significant neurological dysfunction, in addition to MPS IV (Morquio syndrome) characterised by significant skeletal dysfunction.
The attenuated forms of MPS I such as Hurler-Scheie syndrome and Scheie syndrome tend not to receive transplants because of alternative, less risky treatment options (see below) although each case should be considered on an individual basis, based upon the severity of phenotype and age 16 .
Enzyme replacement therapy (ERT)
Recombinant human enzyme is now available as ERT for MPS I (Hurler and Hurler-Scheie syndrome), MPS II, MPS IV (recently) and MPS VI [16] [17] [18] [19] [20] . The enzyme for MPS I and II has been available for approximately ten years. Investigation continues as to the optimal treatment regimen for each enzyme/phenotype. Although exact benefits may differ between MPS types, some basic principles can be stated: ERT produces a variable but often significant improvement in myocardial, airway (reduced soft tissue accumulation and therefore obstructive sleep apnoea [OSA] ) and pulmonary complications together with a reduction in hepatosplenomegaly, improved appearance and some quality of life parameters [16] [17] [18] [19] [20] . Unfortunately ERT does not appear to significantly improve pre-existing neurocognitive dysfunction, skeletal abnormalities or cardiac valvular dysfunction [17] [18] [19] [20] . The former is thought to be due to the enzyme's inability to cross the blood-brain barrier and the latter two issues due to the tissues' relatively poor blood supply. Improved outcome may follow increased dosage regimens and/or commencement of therapy at an earlier age. There are also ongoing clinical trials looking at intrathecal ERT for MPS III and the severe form of MPS II. Further skeletal deterioration often occurs despite current treatment regimens. This means that a significant proportion of MPS patients (particularly MPS IHS, MPS IV and MPS VI) receiving ERT are likely to require correction of major orthopaedic and spinal problems whilst potentially having only partially corrected pre-existing airway and cardiac pathology. The problem of deteriorating skeletal function requiring surgical intervention as the patient gets older can be particularly problematic in patients with Morquio syndrome (MPS IV) 21, 22 . Even in patients currently treated with ERT (this has only recently become available), associated airway disease, particularly tracheal narrowing and kinking, may be severe (see below). Concurrent odontoid hypoplasia and spinal compression due to subdural GAG deposits at other levels make airway management more hazardous and have been associated with perioperative spinal neurological complications 23 . The use of central neuraxial blocks in such cases, even in lower limb surgery, is fraught with problems.
ERT requires weekly infusions via an indwelling venous access device, probably on a lifelong basis. The need for establishment and maintenance of a vascular port can be problematic due to anaesthetic and surgical issues and minor infusion reactions (flushing, rash, fever and headache) and antibody formation also occur 17 . The annual costs of ERT are currently huge 24 .
Improvements in the safety of anaesthesia
As well as improvements in medical therapy for MPS, the safety of anaesthesia in major centres for patients with MPS has improved. This is firstly because of good teamwork, in addition to the routine use of the fibreoptic bronchoscope (FOB) and the availability of supraglottic airway devices. Anaesthetists have also more recently potentially benefited from newer technologies such as videolaryngoscopy (VLS) and diagnostic radiology giving high quality reconstructions of the trachea. But what evidence is there that the anaesthetic care of these patients has improved? Untreated MPS children exhibited a high incidence of difficult airways and intubations [6] [7] [8] [9] . Follow-up reporting from one centre over a decade later found a significantly reduced incidence of airway complications in children with Hurler syndrome treated with HSCT 25 (a 14% incidence of airway complications and no failed intubations). This compared favourably with patients with the attenuated form of MPS I, Hurler-Scheie syndrome, treated with ERT, who had an airway complication rate of 57% and a 3% failed intubation rate 25 . The overall improvement in anaesthetic complications was attributed to a combination of successful medical treatment and an established approach to anaesthesia combining an induction technique utilising maintenance of spontaneous ventilation with an LM either as the airway of choice or as a conduit for a FOB-guided intubation 10, 11 . Similar reductions in anaesthetic complications in treated children have been reported from other institutions [25] [26] [27] [28] . Again children with Hurler syndrome treated with HSCT showed a lower complication rate compared with children with Hurler-Scheie or Hunter syndrome who had received ERT. The complication rate was even higher in untreated children with MPS, especially as they grew older.
The last few years have seen a rapid expansion in the availability of various forms of videolaryngoscopes, each aimed at aiding the management of potentially difficult intubation. Theoretically some or all of these videolaryngoscopes may offer advantages in the management of MPS patients since they may provide a better laryngeal view than with classic direct laryngoscopy and may be both easier and quicker to use when compared to a FOB-guided intubation.
Limited use of the Airtraq TM device (Airtraq, Prodol Meditec, Vizcaya, Spain) has been reported by one centre with their experience in MPS IH children 27 where it was occasionally employed instead of an FOB to complete a failed classic laryngoscopy. Similarly use of the Glidescope TM (GlideScope, Verathon, Bothell, WA, USA) has been reported in a group of MPS patients who received ERT before HSCT 28 . Most significant airway complications occurred before or early in the treatment course. Classic laryngoscopy, FOB-assisted and VLS-assisted intubations were all associated with failed intubations. The overall number of attempted FOBassisted and Glidescope-assisted intubations were relatively small and a significant number of FOB-assisted intubations were described as difficult. The use of the Glidescope was recommended although it is unclear in this report whether this simply reflects a local preference or may reflect a quicker learning curve in its use compared to an FOB. The Glidescope has also been recommended by a centre following their experience with managing Morquio syndrome patients (MPS IV) who often exhibit cervical spine instability, sometimes combined with significant tracheal disease 29 . Recent experience has led them to recommend use of the Glidescope as first choice for potentially difficult intubation. They do however combine use of an FOB via the ETT to inspect for tracheal pathology 21, 22 . There are potential disadvantages to the use of VLS in MPS patients; the presence of pharyngeal GAG deposits can mean that even the most carefully placed laryngoscope blade may cause trauma and bleeding, and performance of a difficult laryngoscopy can lead to a protracted period without direct oxygenation and/or anaesthesia. However, perhaps the most important potential drawback is the specific problem that the anaesthetist is not provided with any information regarding any subglottic or tracheal pathology that may be present. Even if a combined technique with an FOB passed via an ETT is used, any disease proximal to the ETT tip will be missed. The combined LM/FOB technique remains the authors' preferred choice when dealing with new MPS patients or those known to have a difficult airway, particularly in children and adolescents.
The problem of unrecognised subglottic disease may potentially be circumvented by the use of preoperative thoracic computed tomography (CT) scans in selected patients 30 . Multidetector CT scans are able to produce accurate three-dimensional reconstructions of a patient's lower airway and so aid the preoperative planning of anaesthesia 31 . Potentially significant changes to the anaesthetic management as a result of the scan may include the choice of ETT size, tip positioning within the trachea and the use of a fibreoptic bronchoscope to either facilitate intubation or ETT position 30, 31 . Overall, the evidence for a significant advantage in using any particular videolaryngoscope over already established techniques in MPS patients is currently lacking. However it would seem prudent for any anaesthetist managing such patients to have both access to and experience in using at least one type of videolaryngoscope as an alternative method of intubation when confronted with a potentially difficult airway and/or intubation.
Tracheostomy
Severe cases of MPS can be associated with multi-level airway disease combined with thoracic wall deformity and muscular weakness 3, 4, 20 . This can lead to increasingly severe obstruction, respiratory failure and death. A step-wise treatment regimen of surgical correction of any treatable factors (e.g. adenotonsillectomy, GAG deposit resection) followed by supplementary oxygen, mask or nasal continuous positive airway pressure (CPAP)/ bilevel PAP, non-invasive ventilation and finally tracheostomy is recommended 3, 4, 20 . Occasionally, patients require tracheostomy acutely to overcome acute obstruction, or pre-emptively preceding elective surgery 3, 4, 12, 29, 30 . The insertion and management of a tracheostomy in MPS patients is problematic 32, 33 . Surgical access can be severely limited. The tracheostomy is prone to dislodgement and occlusion due to copious secretions. Subsequent infrastomal tracheal stenosis secondary to scarring and GAG deposition, and stomal ulceration and stenosis can become long term issues 32, 33 , making the decision of if and/or when to try decannulation difficult.
Phase three (the challenge of the older patient who has benefited from improved medical management)
Over recent years, more patients with severe forms of MPS disorders are surviving into adulthood and are presenting for continued surgical intervention as mentioned previously. In order to illustrate this new and emerging phase of the management of the MPS sufferer and the extreme challenge that they can present to the anaesthetist amongst others we include three case studies which illustrate the importance of teamwork, preoperative planning and the often difficult decisions that are involved in managing this group of patients. These cases deal mainly with airway issues as the airway is often the most challenging aspect and involves careful management for a successful outcome.
Case reports
Written consent was given for all cases, including publication of photographs and imaging.
Case one
A 27-year-old man with Hurler-Scheie syndrome required a C1-4 laminectomy and occipitocervical fusion (C0-C5) for cervical stenosis (secondary to GAG deposits) with signs of early cervical myelopathy (Figure 1 ). He had received ERT for ten years since it became available. A progressively more difficult airway had been noted during multiple operations as a child culminating at the age of 21 with the need for an awake fibreoptic intubation. He had severe OSA, treated with nocturnal CPAP and a documented restrictive respiratory deficit to 40% of normal. Physical examination revealed a short man of normal intellect, mildly limited neck movement but severe micrognathia (Mallampati score of four).
A multidisciplinary discussion involving spinal and ear, nose and throat (ENT) surgeons, neurosurgeons, paediatric and adult anaesthetists and intensivists ensued followed by a prolonged discussion with the patient regarding the anaesthetic options available. Whilst the patient was extremely anxious about another awake intubation he was desperate to avoid a tracheostomy. The ENT opinion was that a tracheostomy would be extremely difficult and may involve sternal splitting. A plan was agreed upon where an awake nasal fibreoptic intubation under sedation would be attempted to secure the airway. If this was unsuccessful and it was felt safe to proceed then a fibreoptic intubation via an LM under spontaneous ventilation would be utilised. Awake intubation was achieved with some difficulty under combined midazolam and ketamine sedation and topical local anaesthesia. Subsequent direct laryngoscopy using either a standard Macintosh or CMAC TM videoscope (Storz, Tuttlingen, Germany) revealed a grade 4 larynx. Surgery proceeded in the prone position for a total of six hours. At the end of surgery, when supine, marked tongue and lip swelling was noted. It was impossible to place a blade in the oropharynx. The patient was left intubated and ventilated in the adult intensive care unit in a 45 degree head-up position and received regular dexamethasone. An airway assessment the following day showed a significant reduction in lip and tongue swelling but a decision was taken to postpone extubation for a further day in the hope of optimising conditions. The next day the patient underwent a planned extubation in theatre with the presence of the anaesthetic and ENT teams. The perioral swelling had disappeared and the patient was awake and cooperative. Nasendoscopy was performed to inspect the larynx and topical lignocaine and vasoconstrictors were applied to the naso-and oropharynx. A nasal airway was passed, and a guide-wire was positioned in the trachea 34 via the nasal ETT following topical lignocaine to the trachea and the patient was extubated awake without complication. 
Case two
A 25-year-old woman with Hurler-Scheie syndrome presented for mitral valve replacement. She was of extreme short stature and weighed 26 kg despite being commenced on ERT aged twelve years. Previous anaesthetic history was noteworthy for grade 4 laryngoscopy with a narrowed glottis requiring fibreoptic intubation via an LM when 16 years old and an episode of post-extubation negative pressure pulmonary oedema following a subsequent anaesthetic. Following cervical decompression of spinal GAG deposits aged 18 years, she required three days postoperative intubation. At 20 years of age she presented for a corneal transplant and revision of her Portacath TM (Smiths Medical, Ashford, Kent, UK). On the first attempt at anaesthesia the glottic opening was again noted to be very narrowed and the procedure was abandoned to allow further discussion with the patient. She remained insistent that she wanted this procedure despite refusing consent for a possible tracheostomy. At a subsequent anaesthetic, involving two experienced paediatric anaesthetists, she was successfully intubated fibreoptically via an LM. At this time significant subglottic narrowing, in addition to the glottic changes, was noted (Figures 2a and 2b) . Intraoperative dexamethasone and topical vasoconstrictors facilitated a rapid and successful extubation. At the age of 25 she had become increasingly breathless due to severe mitral stenosis and mild mitral regurgitation with pulmonary hypertension. She also had mild to moderate aortic stenosis. A mitral valve replacement was planned and the case was discussed by a multidisciplinary team involving paediatric specialists and the adult congenital heart team.
The preoperative plan was to perform a fibreoptic examination of her whole airway followed by intubation as previously described. Should the upper airway be found to still be significantly narrowed a tracheostomy (to facilitate any prolonged period of ventilation if required) would be performed after the cardiac surgery had been completed. Motor evoked potential spinal cord monitoring would also be used because of the risk of spinal cord ischaemia while on cardiopulmonary bypass.
At induction similar findings as previously described were noted and she was successfully intubated with a 5.0 Microcuff ETT (Halyard Health UK Limited, Surrey, UK). Her cardiac surgery was completed and a Bivona size 5.5 hyperflex flange tracheostomy tube (Smiths Medical, Ashford, Kent, UK) inserted. She required five days of postoperative ventilatory support. Three weeks postoperatively she required rewiring of her sternum. Her tracheostomy was subsequently changed to a Montgomery T-tube (Montgomery Safe T-Tube, Boston Medical Products, Westborough, MA, USA) and she was successfully decannulated six weeks following her original operation. Examination of her upper airway revealed minimal damage to the glottis and subglottis. She made an excellent recovery.
Case three
An 18-year-old boy (40 kg) with Hunter syndrome presented for airway assessment. He had been on ERT for ten years and was of normal intelligence but with somatic features of advanced mucopolysaccharidosis (Figure 3a) . He gave a history of hoarse voice, stertorous breathing and occasional choking episodes on eating. He had moderately severe OSA with daytime somnolence. Echocardiography revealed mild aortic valve disease and a CT of his thorax revealed a tortuous trachea with areas of narrowing in the subglottic and distal tracheal regions (Figure 3b) .
A formal endoscopic airway examination under anaesthesia and adenoidectomy was planned.
Following anaesthetic induction (sevoflurane with maintenance of spontaneous ventilation) airway obstruction and arterial desaturation to 50% occurred. Use of oral, nasal airways with CPAP and then LM airways failed to resolve the obstruction. The procedure was abandoned and the patient allowed to awaken with resolution of his obstruction and hypoxaemia. Recovery was uneventful. However, he presented again following a severe episode of airway obstruction at home. After a multidisciplinary paediatric team discussion a tracheostomy was planned. An awake fibreoptic nasal intubation was performed with some difficulty under combined sedation and topical lignocaine. Insertion of the tracheostomy (size 5.0) was surgically very challenging due to his short neck and thickened tissues. Following establishment of an adequate tract this was then changed to a Montgomery T-tube to help stent both the subglottic and distal tracheal narrowing present. He was discharged home after two months in hospital.
The three cases presented here help illustrate both the problems that have traditionally challenged only paediatric anaesthetists when managing children with MPS disease together with many of the newer issues that are now presenting themselves. The need for permanent intravenous access to deliver ERT combined with its failure to resolve some significant clinical problems will prompt the need for continued, multiple anaesthetic interventions. Current ERT regimens fail to correct or retard skeletal and cartilaginous problems such as poor growth, odontoid hypoplasia, thoracolumbar scoliosis, mandibular hypoplasia and temporomandibular joint problems. As well as potentially requiring surgical correction themselves, these comorbidities are associated with deteriorating airway and respiratory function. The three cases presented here had been receiving ERT for several years but exhibited only partial resolution of their clinical problems. Whether this phenomenon will disappear with the adoption of newer ERT strategies is currently unclear. In addition, ERT for the treatment of Morquio syndrome has only recently become available in many countries and funding is not universally available. It cannot be said with any certainty that similar problems will not occur with this group even if treatment is started at a young age. The majority of the procedures described in our three patients were performed by a paediatric team experienced in the management of MPS patients, usually within a paediatric hospital. However for two of the procedures the type of surgery and local services available required that surgery was performed in an adult service. In each case a mixed team of relevant adult and paediatric specialists was involved. There are now established guidelines for the management of difficult/failed intubation and extubation in both adult and paediatric practice 34 . Adult airway specialists possess significant experience in awake FOB techniques. However MPS patients may warrant special consideration. The potential presence of significant multi-level (including nasopharyngeal) obstruction together with possible impaired or immature cognitive function can make the choice of intubation method challenging. Current adult guidelines advocate the 'front of neck access' route to establishing an airway when supraglottic methods have failed. Many MPS patients, even after treatment, are extremely challenging tracheostomies, particularly when presented to clinicians unfamiliar with the condition and/or in emergency conditions. As illustrated here the choice of when or whether to establish a surgical airway can be difficult and requires experienced assessment on an individual case basis.
Discussion
The outlook for children with many of the subtypes of MPS has improved considerably over the past ten years. Successful HSCT, particularly for Hurler syndrome, has revolutionised the treatment of a disease that used to be universally fatal. Earlier diagnosis combined with improved recipient marrow preparation and transplant techniques utilising available compatible donor cells have reduced transplant-related morbidity and mortality and improved long-term outcome. Even earlier diagnosis, possibly including antenatal diagnosis, combined with non-related HLA-matched donor cells may improve results further due to a combination of earlier transplant before any irreversible changes have occurred, together with a more effective transplant producing higher cellular levels of functioning enzyme. This success has significantly reduced the frequency of severely affected children presenting for anaesthesia. Such patients may well present in the future for surgery relating to cardiac valvular or skeletal problems but they are less likely to possess severe airway problems.
The availability of ERT for many of the MPS subtypes where HSCT is not a viable option has considerably enhanced the outlook for these patients. However the lack of improvement in certain systems, particularly neurocognitive function, skeletal development and cardiac valvular pathology has meant that an increasing number of children with MPS are now growing into early adulthood with the need for corrective surgery with sometimes variable improvement in upper and lower airway pathology as well as cardiac function.
The incidence of MPS disease is rare (overall rate approximately 1/25,000) making it unlikely that such patients will present to the general anaesthetist on a regular basis. The benefits of early diagnosis and correct treatment mean that all patients with suspected or proven disease should be referred to a specialist metabolic centre for investigation and ongoing management. Any patient with a new diagnosis or proven pre-existing significant comorbidity should be referred to that centre for any required surgical and anaesthetic interventions. Joint care, including provision of anaesthetic services, is probably best provided on an individual patient basis following discussion between the specialist centre and referring hospital once the diagnosis and necessary initial investigations have been completed.
The anaesthetic management of patients with MPS disease was previously the realm of the specialist paediatric anaesthetist, often working as an important part of a multidisciplinary team led by a specialist in paediatric metabolic medicine. Adoption of this practice allowed the development of high quality treatment in specialist paediatric centres. However, this new cohort of older patients may now present for surgery to surgeons and anaesthetists with a predominantly adult patient base, who may be unaware of or unfamiliar with the potential problems involved. Such teams will usually be expecting to work in an adult patient environment including the delivery of perioperative care such as intensive care. The patients themselves on the other hand, although adult in age, will usually have been used to their long-term care in a paediatric centre. This is of particular relevance for those with any degree of neurocognitive impairment. Provision of optimal care in such situations will probably involve shared care between interested and suitably experienced clinicians from both specialist adult and paediatric airway practice. Creation of a subspecialty akin to that already established with adult congenital heart disease may not be feasible considering the rarity of the disorder. However a similar team approach would allow optimisation of care for these rare but potentially difficult cases. The exact details of whom, where and how such a team would operate would depend upon already established local services and expertise. Not all specialist paediatric or adult centres possess all of the potentially necessary surgical specialties on one site. For most centres some degree of intelligent compromise will be required if we are to successfully manage this new cohort of MPS patients.
